Advertisement
Research Article

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

  • Clara I. Aceves-Luquero,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Anupriya Agarwal,

    Affiliation: Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon, United States of America

    X
  • Juan L. Callejas-Valera,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Laura Arias-González,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Azucena Esparís-Ogando,

    Affiliation: Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain

    X
  • Luis del Peso Ovalle,

    Affiliation: Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain

    X
  • Itxaso Bellón-Echeverria,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Miguel A. de la Cruz-Morcillo,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Eva M. Galán Moya,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Inmaculada Moreno Gimeno,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Juan C. Gómez,

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Michael W. Deininger,

    Affiliation: Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon, United States of America

    X
  • Atanasio Pandiella,

    Affiliation: Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain

    X
  • Ricardo Sánchez Prieto mail

    ricardo.sanchez@uclm.es

    Affiliation: CRIB/Facultad de Medicina, UCLM, Albacete, Spain

    X
  • Published: July 01, 2009
  • DOI: 10.1371/journal.pone.0006124

Reader Comments (0)

Post a new comment on this article